March 2026

Viridian Stock Crashes 34% After Eye Drug Efficacy Disappoints The brutal reality of biotech investing was on full display this week as Viridian Therapeutics saw its stock price plunge by a staggering 34% in a single day. The catalyst? Clinical trial results for its promising eye disease drug, VRDN-001, which delivered a paradoxical blow: it […]

Viridian’s Thyroid Eye Disease Drug Stumbles, Stock Plummets 30% The race to challenge Amgen’s blockbuster thyroid eye disease (TED) drug, Tepezza, just hit a major roadblock. Viridian Therapeutics, a biotech firm that had been gaining significant attention from investors, saw its stock price crater by over 30% following the release of disappointing early-stage clinical trial

Viridian’s Elegrobart Succeeds in Phase 3 Thyroid Eye Disease Trial In a significant breakthrough for patients with Thyroid Eye Disease (TED), Viridian Therapeutics has announced positive topline results from its pivotal Phase 3 REVEAL1 clinical trial. The trial evaluated the efficacy and safety of elegrobart, the company’s novel investigational monoclonal antibody, in treating active, moderate-to-severe

Ultra-Processed Foods Linked to Heart Disease and Glaucoma Risk For years, nutritionists have urged us to “eat clean” and avoid packaged snacks and ready-made meals. Now, a powerful new study provides some of the strongest evidence yet that this advice is not just about waistlines—it’s a matter of life and death for your heart and

Kodiak Sciences’ Positive Eye Disease Data: Should Investors Buy the Rally? The biotech sector is no stranger to dramatic swings, and Kodiak Sciences Inc. (KOD) just provided a textbook example. After announcing positive topline data from its pivotal GLEAM and GLIMMER studies for its lead candidate, **tarcocimab tedromer**, in diabetic eye diseases, the company’s stock

Kodiak Sciences Stock Surges After Positive Eye Disease Trial Results In a significant development for both patients and investors, Kodiak Sciences Inc. (NASDAQ: KOD) saw its stock price rocket upwards following the announcement of highly promising Phase III clinical trial data. The biopharmaceutical company, focused on novel treatments for retinal diseases, reported that its lead

BYD’s God’s Eye Self-Driving System Faces Major Technical Setbacks The race for autonomous driving supremacy is a marathon, not a sprint, and even the frontrunners can stumble. BYD, the Chinese electric vehicle giant that recently dethroned Tesla in global EV sales, is facing a significant hurdle in its quest for technological dominance. Its highly anticipated

Eye Floaters Could Signal a Serious Retinal Detachment Risk We’ve all experienced them at some point: those tiny, shadowy specks, cobwebs, or squiggly lines that drift across your field of vision, especially when you look at a bright, plain surface like a blue sky or a white wall. Known as eye floaters, they are often

How a Routine Eye Test Saved a Life by Detecting a Brain Tumor We often think of an eye exam as a simple check for glasses or a screening for common conditions like cataracts. It’s a routine part of healthcare, sometimes even postponed when life gets busy. But what if that 30-minute appointment could do

Ocugen Stock Drops After Eye Disease Gene Therapy Trial Disappoints The world of biotechnology is a high-stakes arena, where a single clinical trial result can send a company’s valuation soaring or plummeting. This volatile reality hit home for Ocugen, Inc. (NASDAQ: OCGN) this week, as the company’s shares experienced a sharp decline following the release